Kim 2015b.

Methods	A prospective, multicentre, open‐label cohort study of 116 children with ADHD treated with OROS methylphenidate for 12 weeks
Participants	Number of participants screened: not stated Number of participants included: 143 Number of participants followed up: 116 Number of withdrawals: 27 Diagnosis of ADHD: DSM‐IV (subtype: combined (36.2%), hyperactive‐impulsive (5.2%), inattentive (33.6%), NOS (25%)) Age: mean 9.4, range: 6‐18 years old IQ: mean 108.9 (SD 16.0) Sex: 100 males, 16 females Methylphenidate‐naïve: 89.7% Ethnicity: not stated Country: Korea Comorbidity: depression (5.2%), anxiety (7.7%), tic disorder (7.7%), ODD (10.3%) Comedication: not stated Sociodemographics: not stated Inclusion criteria ADHD diagnosis (any subtype) according to DSM‐IV Exclusion criteria Patients with an IQ less than 70 (as assessed by the K‐Wechsler Intelligence Scale for Children, Third Edition) Seizure disorders, brain injuries, psychotic disorders, pervasive developmental disorders, or serious medical or neurologic conditions Children who were taking SSRIs or antipsychotics within 4 weeks prior to study
Interventions	Methylphenidate type: osmotic release oral system (OROS) Mean methylphenidate dosage: average daily dose increased from 19.20 (SD 3.11) mg/d (0.64 (SD 0.18) mg/kg per day) at week 1 to 34.13 (SD 13.80) mg/d (1.03 (SD 0.3318) mg/kg per day) at the end of 12 weeks of dosing Administration schedule: not stated Duration of intervention: 12 weeks Treatment compliance: 12 patients dropped out because of medication non‐compliance
Outcomes	8 participants dropped out because of adverse events (29.6%)
Notes	Sample calculation: no Ethics approval: yes Funding: this study has been sponsored by Janssen, Korea Vested interests/authors' affiliations: the authors have no conflicts of interest to declare. Key conclusions of the study authors: treatment with OROS‐MPH was associated with symptomatic functional changes that were moderately correlated; therefore, symptomatic functional outcomes appear to be partially overlapped but distinct domains. Consequently, functional measures should be incorporated as important outcome measures in future treatment studies; the importance of treatments targeting functional improvement should be emphasised in the treatment of children with ADHD Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no Supplemental information regarding adverse events requested through personal email correspondence with the authors in June 2016 with no reply